MedTrace Logo

Blood Volume Analysis and Renal Outcomes in Hemodialysis

NCT02717533 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2016-03-23

No results posted yet for this study

Summary

The objective of the proposed study is to demonstrate that serial blood volume analysis (BVA) using RI-BVA (BVA-100, Daxor, NY) can be used to guide changes in prescription of dry weight for hemodialysis patients. The knowledge of a patient's ideal BV and degree of hypervolemia using these measurements can be used to change the prescription of DW in an objective way instead of the current standard of practice, which is based on subjective prescription of dry weight. A first study was conducted to determine the rate of plasma volume (PV) re-expansion for each patient as a guide to rate of fluid removal (results published, refer to citations). A second study was conducted in order to assess the value of a BVA measurement in guiding prescription of clinical DW. A follow up BVA would then be done in order to check if patients were closer to ideal BV than prior to changing dry weight.

Conditions

  • End Stage Renal Failure on Dialysis
  • Actual Impaired Fluid Volume
  • Kidney Failure

Interventions

OTHER

dry weight adjustment

dry weight change to match ideal blood volume obtained by blood volume measurement.

Sponsors & Collaborators

  • Daxor Corporation

    collaborator INDUSTRY

  • VA New York Harbor Healthcare System

    lead FED

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2014-10-31
Completion
2015-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02717533 on ClinicalTrials.gov